FLEXENABLE TECHNOLOGY LIMITED

Their core work

FlexEnable is a Cambridge-based SME that develops and manufactures organic thin-film transistor (OTFT) technology — the semiconductor layer that makes flexible, lightweight, and printable electronics possible. Their core capability is producing high-mobility organic semiconductor materials and translating them into functional devices using scalable processes like roll-to-roll (R-2-R) and photolithography. In H2020 projects they contributed this platform to two distinct application domains: clinical-grade bio-electronic sensors for point-of-care diagnostics, and flexible photovoltaic and display modules for wearable and energy applications. They are a technology enabler: other partners in a consortium bring the system architecture or application domain, while FlexEnable supplies the organic semiconductor layer and the know-how to manufacture it reliably.

What they specialise in

How they've shifted over time

FlexEnable entered H2020 through a health-technology lens: their first project (SiMBiT, 2019) applied organic TFTs as electrolyte-gated field-effect sensors for clinical diagnostics, with keywords centered on single-molecule detection and point-of-care testing. Their second project (RoLA-FLEX, 2020) pivoted toward energy and consumer electronics, with keywords shifting to organic photovoltaics, flexible displays, wearable electronics, and industrial manufacturing processes (laser, R-2-R). The underlying organic semiconductor platform is the same in both cases, but the trajectory suggests FlexEnable is broadening its addressable markets from medical devices into the energy and wearables space, likely following commercial demand for their OTFT IP.

FlexEnable is moving from niche medical-sensing applications toward scalable, mass-market flexible electronics manufacturing — making them an increasingly attractive partner for energy, wearables, and display consortia that need proven organic semiconductor expertise.

How they like to work

FlexEnable participates exclusively as a consortium partner — they have never coordinated an H2020 project, which is typical for deep-technology SMEs that supply a specific material or process capability rather than leading application development. Despite only two projects, they have engaged with 19 distinct partners across 11 countries, indicating that their organic semiconductor platform is genuinely sought after as a specialist ingredient in large multi-partner consortia. They appear to operate as a focused technology contributor: others build the system, FlexEnable provides the organic electronics layer.

With 19 unique partners across 11 countries from just 2 projects, FlexEnable has an unusually wide network for its size — roughly 10 partners per project, suggesting they join large consortia rather than small bilateral collaborations. Their geographic reach spans much of Europe, consistent with the international nature of the OLAE and flexible electronics research community.

What sets them apart

FlexEnable occupies a rare position as a commercial SME with proprietary organic thin-film transistor technology that is both scientifically credible (EU-funded research partnerships) and industrially deployable (R-2-R and photolithography processes). Most OTFT work happens in universities; FlexEnable offers the bridge between academic materials science and manufacturable product — which makes them valuable to any consortium that needs to demonstrate a working prototype, not just a paper. For a consortium builder, they bring IP, process know-how, and a commercial stake in the outcome, which is a combination that is hard to find in this technology niche.

Highlights from their portfolio

• RoLA-FLEX
  Largest funding award (EUR 113,519) and the broadest technology scope — combining three manufacturing processes (R-2-R, photolithography, laser) with three application markets (photovoltaics, displays, wearables), making it the clearest showcase of FlexEnable's industrial manufacturing ambition.
• SiMBiT
  Demonstrates FlexEnable's ability to enter a highly regulated, precision-demand domain (clinical single-molecule diagnostics) with their printable organic TFT platform, showing the technology's sensitivity well beyond consumer electronics.